Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • PAD4-IN-2 TFA: Targeted Inhibition for Tumor Microenvironmen

    2026-05-08

    PAD4-IN-2 TFA: Targeted Inhibition for Tumor Microenvironment Studies

    Setup and Principle: Precision PAD4 Inhibition in Oncology Research

    PAD4-IN-2 TFA, also known as Compound 5i TFA, is a next-generation PAD4 enzymatic activity inhibitor engineered for highly selective, tumor-targeted research applications. Its meta-phenylboronic acid (m-PBA) modification enables specific binding to sialic acid residues abundant on tumor cell surfaces, ensuring minimal uptake in normal tissues (paper). Mechanistically, this PAD4 inhibitor trifluoroacetate suppresses histone H3 citrullination (H3cit) and neutrophil extracellular trap (NET) formation, both of which are implicated in tumor progression and metastasis.

    Crucially, PAD4-IN-2 TFA achieves potent inhibition of PAD4 (IC₅₀: 1.94 ± 0.65 μM) without direct cytotoxicity at concentrations up to 100 μM, making it ideal for dissecting the PAD4-H3cit-NETs axis in the tumor immune microenvironment (product_spec).

    Step-by-Step Experimental Workflow

    1. Preparation and Handling:
      Store PAD4-IN-2 TFA at -20°C. Prepare fresh working solutions immediately before use; avoid repeated freeze-thaw cycles for optimal activity (product_spec).
    2. In Vitro PAD4 Activity Assay:
      Add PAD4-IN-2 TFA to enzyme preparations or cell lysates at 1–10 μM to assess dose-dependent inhibition of PAD4-mediated H3cit. Use appropriate controls (e.g., vehicle, positive PAD4 inhibitor like YW3-56) for benchmarking (paper).
    3. Cellular Uptake and Selectivity Assessment:
      Incubate 4T1 breast cancer cells and normal cell lines with PAD4-IN-2 TFA for 30–120 min. Use confocal microscopy or flow cytometry to verify membrane localization and selective uptake by tumor cells (workflow_recommendation).
    4. NET Formation Inhibition Assay:
      Treat neutrophils or co-cultures with PAD4-IN-2 TFA (up to 100 μM) and induce NETosis (e.g., PMA stimulation). Quantify NETs by immunofluorescence staining for H3cit and extracellular DNA (isomaltsyn.com).
    5. In Vivo Antitumor Efficacy:
      Administer PAD4-IN-2 TFA to S180 or 4T1 tumor-bearing mice at 10 μmol/kg intraperitoneally. Monitor tumor growth, metastasis, and immune cell populations (source: paper).

    Protocol Parameters

    • PAD4 activity assay | 1.94 μM (IC₅₀) | in vitro enzymatic inhibition | Optimal for detecting PAD4-specific effects without off-target activity | paper
    • Cell migration assay | 1–50 μM | 4T1 breast cancer cell migration inhibition | Doses up to 100 μM show no direct cytotoxicity, allowing clear readout of migration/metastasis inhibition | product_spec
    • In vivo dosing | 10 μmol/kg, i.p., daily | S180 sarcoma or 4T1 breast cancer models | Maximizes tumor inhibition (49.2%) with minimal toxicity, outperforming reference PAD4 inhibitor YW3-56 | paper

    Key Innovation from the Reference Study

    The reference study (paper) introduced a paradigm-shifting approach by modifying PAD4 inhibitors with m-PBA, dramatically increasing tumor specificity via sialic acid-mediated uptake. This enables researchers to selectively inhibit the PAD4-H3cit-NETs pathway in tumor-infiltrating neutrophils and tumor cells, without affecting normal tissues. The practical implication is a robust reduction in tumor growth and metastasis, while preserving healthy immune function and minimizing systemic toxicity. For assay design, this means researchers can use PAD4-IN-2 TFA at higher concentrations and in vivo doses than traditional PAD4 inhibitors, without confounding toxicity or off-target effects—unlocking clearer insights into NET biology and tumor immune modulation.

    Advanced Applications and Comparative Advantages

    PAD4-IN-2 TFA's unique targeting makes it indispensable for studies requiring:

    • Dissection of NET Formation Inhibition: Quantitative measurement of NETs in tumor microenvironments, particularly in neutrophil-rich tumors, without systemic neutrophil depletion (isomaltsyn.com).
    • Tumor Immune Microenvironment Modulation: Analysis of shifts in neutrophil subpopulations and M1/M2 macrophage ratios following PAD4 inhibition, using CyTOF or single-cell sequencing (precisionfda.net).
    • 4T1 Breast Cancer Cell Migration Inhibition: Real-time tracking of migratory and metastatic potential in vitro and in vivo, with minimal confounding cytotoxicity (cy7-azide.com).
    Compared to older PAD4 inhibitors like YW3-56, PAD4-IN-2 TFA delivers superior safety (no hepatotoxicity or nephrotoxicity per serum markers: Cr, BUN, AST, ALT) and a 49.2% tumor inhibition rate in S180 models (source: paper).


    For researchers aiming to dissect the interplay between chromatin modification, innate immunity, and cancer metastasis, PAD4-IN-2 TFA—available from APExBIO—enables integrated workflows across cell-based, molecular, and in vivo platforms.

    Troubleshooting and Optimization Tips

    • Solubility and Handling: Always prepare fresh solutions and avoid long-term storage in buffer, as PAD4-IN-2 TFA is not stable in aqueous solution for extended periods (source: product_spec).
    • Selectivity Controls: When observing minimal effect in normal cells, confirm sialic acid expression and m-PBA targeting via competitive inhibition or use of sialidase pretreatment (workflow_recommendation).
    • Assay Sensitivity: For low NET readouts, verify neutrophil viability and optimize stimulation protocols (e.g., PMA dose, incubation time). Consider including PAD4 knockout or YW3-56 as additional controls (isomaltsyn.com).
    • In Vivo Dosing: For new mouse models, titrate dosing starting at 10 μmol/kg and monitor body weight and serum liver/kidney markers regularly to confirm absence of toxicity (source: paper).
    • Tumor Uptake Validation: Use fluorescently labeled analogs or direct confocal imaging to confirm tumor-specific accumulation (workflow_recommendation).

    Interlinking Related Resources

    The applied guide at isomaltsyn.com complements this article by offering additional troubleshooting strategies and mechanistic explanations for NET formation assays. In contrast, the resource at cy7-azide.com provides stepwise protocols for advanced tumor microenvironment profiling, focusing on immune modulation workflows. The detailed comparative analysis at precisionfda.net extends these insights by benchmarking PAD4-IN-2 TFA against legacy PAD4 inhibitors, highlighting the impact of m-PBA modification on selectivity and safety.

    Future Outlook: Implications for Tumor Immunology

    The selective, low-toxicity profile of PAD4-IN-2 TFA opens new avenues for mechanistic dissection of NETs and immune modulation in cancer models. As the reference study demonstrated, leveraging m-PBA modifications for targeted delivery can transform the therapeutic index of PAD4 inhibitors—enabling high-dose, tumor-specific interventions with minimal off-target effects (paper). Continued integration of PAD4-IN-2 TFA into in vivo and ex vivo tumor microenvironment studies is poised to clarify the role of PAD4-H3cit-NETs in cancer progression and inform the next generation of immuno-oncology therapeutics.